Literature DB >> 23015719

Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.

Timothy J Powell1, Jonathan D Silk, Jane Sharps, Ervin Fodor, Alain R M Townsend.   

Abstract

There is a need for vaccines that can protect broadly across all influenza A strains. We have produced a pseudotyped influenza virus based on suppression of the A/PR/8/34 hemagglutinin signal sequence (S-FLU) that can infect cells and express the viral core proteins and neuraminidase but cannot replicate. We show that when given by inhalation to mice, S-FLU is nonpathogenic but generates a vigorous T cell response in the lung associated with markedly reduced viral titers and weight loss after challenge with H1 and H3 influenza viruses. These properties of S-FLU suggest that it may have potential as a broadly protective A virus vaccine, particularly in the setting of a threatened pandemic before matched subunit vaccines become available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015719      PMCID: PMC3503098          DOI: 10.1128/JVI.01820-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol).

Authors:  Jorge Fernandez de Castro; John V Bennett; Hector Gallardo Rincon; M T Alvarez Y Munoz; Luis Alfonso E Partida Sanchez; Jose Ignacio Santos
Journal:  Vaccine       Date:  2005-01-11       Impact factor: 3.641

3.  Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus.

Authors:  Timothy J Powell; Tara Strutt; Joyce Reome; Joseph A Hollenbaugh; Alan D Roberts; David L Woodland; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

4.  Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

Authors:  Robert B Belshe; Christopher S Ambrose; Tingting Yi
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

5.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 6.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

7.  The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

8.  Introduction of silent mutations into the NP gene of influenza A viruses as a possible strategy for the creation of a live attenuated vaccine.

Authors:  Darisuren Anhlan; Eike-Roman Hrincius; Christoph Scholtissek; Stephan Ludwig
Journal:  Vaccine       Date:  2012-05-07       Impact factor: 3.641

9.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.

Authors:  Carmela De Santo; Mariolina Salio; S Hajar Masri; Laurel Yong-Hwa Lee; Tao Dong; Anneliese O Speak; Stefan Porubsky; Sarah Booth; Natacha Veerapen; Gurdyal S Besra; Hermann-Josef Gröne; Frances M Platt; Maria Zambon; Vincenzo Cerundolo
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

View more
  48 in total

Review 1.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

2.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

3.  Influenza vaccination and the 'diversity paradox'.

Authors:  Craig P Thompson; Uri Obolski
Journal:  Hum Vaccin Immunother       Date:  2018-09-21       Impact factor: 3.452

Review 4.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

5.  Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine.

Authors:  Aitor Nogales; Laura Rodriguez; Caroline Chauché; Kai Huang; Emma C Reilly; David J Topham; Pablo R Murcia; Colin R Parrish; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 6.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

7.  A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.

Authors:  Hiroaki Katsura; Zhenyu Piao; Kiyoko Iwatsuki-Horimoto; Yukihiro Akeda; Shinji Watanabe; Taisuke Horimoto; Kazunori Oishi; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

8.  Focused antibody response to influenza linked to antigenic drift.

Authors:  Kuan-Ying A Huang; Pramila Rijal; Lisa Schimanski; Timothy J Powell; Tzou-Yien Lin; John W McCauley; Rodney S Daniels; Alain R Townsend
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

9.  Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.

Authors:  Aitor Nogales; Kevin Chiem; Michael Breen; Marta L DeDiego; Colin R Parrish; Luis Martínez-Sobrido
Journal:  Methods Mol Biol       Date:  2022

Review 10.  An Antigenic Thrift-Based Approach to Influenza Vaccine Design.

Authors:  Jai S Bolton; Hannah Klim; Judith Wellens; Matthew Edmans; Uri Obolski; Craig P Thompson
Journal:  Vaccines (Basel)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.